April 26 | 2021
Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million
Read more
April 24 | 2021
Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021.
Read more
April 23 | 2021
Notice to attend the Annual General Meeting of 2cureX AB
Read more
April 23 | 2021
The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021
Read more
March 2 | 2021
2cureX Clinical Newsletter
Read more
March 1 | 2021
2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.
Read more
February 25 | 2021
2cureX publishes year-end report for 2020.
Read more
February 4 | 2021
IndiTreat® selected to prestigious multinational ovarian cancer project.
Read more
January 28 | 2021
2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO.
Read more
January 21 | 2021
Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more
January 5 | 2021
2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO
Read more
December 23 | 2020
Key achievements in 2020 – an IndiTreat ® Launch year
Read more
November 26 | 2020
2cureX publishes interim report for the third quarter of 2020.
Read more
November 26 | 2020
2cureX launches new website
Read more
November 11 | 2020
2cureX presents commercial roadmap 2021 – 2023
Read more
November 5 | 2020
Announcement from 2cureX extra general meeting
Read more
October 14 | 2020
Notice of extraordinary general meeting in 2ureX AB
Read more
October 1 | 2020
Last patient successfully enrolled in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more